[go: up one dir, main page]

WO2003051366A3 - 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer - Google Patents

3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer Download PDF

Info

Publication number
WO2003051366A3
WO2003051366A3 PCT/US2002/039915 US0239915W WO03051366A3 WO 2003051366 A3 WO2003051366 A3 WO 2003051366A3 US 0239915 W US0239915 W US 0239915W WO 03051366 A3 WO03051366 A3 WO 03051366A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
cancer
treatment
alkoxy
kinase inhibitors
Prior art date
Application number
PCT/US2002/039915
Other languages
French (fr)
Other versions
WO2003051366A2 (en
Inventor
Qun Li
Keith W Woods
Gui-Dong Zhu
John P Fischer
Jianchun Gong
Tongmei Li
Viraj Gandhi
Sheela A Thomas
Garrick Packard
Xiaohong Song
Jason N Abrams
Robert Diebold
Jurgen Dinges
Charles Hutchins
Vincent S Stoll
Saul H Rosenberg
Vincent L Giranda
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to JP2003552299A priority Critical patent/JP2005516927A/en
Priority to CA002470214A priority patent/CA2470214A1/en
Priority to EP02790126A priority patent/EP1463505A2/en
Priority to AU2002353147A priority patent/AU2002353147A1/en
Publication of WO2003051366A2 publication Critical patent/WO2003051366A2/en
Publication of WO2003051366A3 publication Critical patent/WO2003051366A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds having the formula (I), are useful for inhibiting protein kinases and for the treatment of cancer. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
PCT/US2002/039915 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer WO2003051366A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003552299A JP2005516927A (en) 2001-12-13 2002-12-12 3- (Phenyl-alkoxy) -5- (phenyl) -pyridine derivatives and related compounds as kinase inhibitors for cancer treatment
CA002470214A CA2470214A1 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
EP02790126A EP1463505A2 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
AU2002353147A AU2002353147A1 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34135601P 2001-12-13 2001-12-13
US2336301A 2001-12-13 2001-12-13
US10/023,363 2001-12-13
US34147401P 2001-12-17 2001-12-17
US10/295,833 US20030187026A1 (en) 2001-12-13 2002-11-18 Kinase inhibitors
US10/295,833 2002-11-18
US10/317,914 US6831175B2 (en) 2001-12-13 2002-12-12 Kinase inhibitors

Publications (2)

Publication Number Publication Date
WO2003051366A2 WO2003051366A2 (en) 2003-06-26
WO2003051366A3 true WO2003051366A3 (en) 2004-03-25

Family

ID=29554492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039915 WO2003051366A2 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer

Country Status (2)

Country Link
US (2) US20030187026A1 (en)
WO (1) WO2003051366A2 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7524957B2 (en) 2001-08-17 2009-04-28 Astrazeneca Ab Compounds effecting glucokinase
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7655662B2 (en) 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US8183371B2 (en) 2009-10-30 2012-05-22 Janssen Pharmaceutica Nv Pyrazines as delta opioid receptor modulators
US8394809B2 (en) 2009-10-30 2013-03-12 Janssen Pharmaceutica, Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
US8513271B2 (en) 2009-10-30 2013-08-20 Janssen Pharmaceutica, Nv Pyrimidine compounds as delta opioid receptor modulators
US8846714B2 (en) 2009-12-21 2014-09-30 Samumed, Llc 1H-pyrazolo[3,4-β]pyridines and therapeutic uses thereof
US8883822B2 (en) 2012-05-04 2014-11-11 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8987298B2 (en) 2012-04-04 2015-03-24 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US9221793B2 (en) 2011-09-14 2015-12-29 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US9381192B2 (en) 2009-08-10 2016-07-05 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9475807B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof
US9475825B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9493487B2 (en) 2014-09-08 2016-11-15 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US9540398B2 (en) 2014-09-08 2017-01-10 Samumed, Llc 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9546185B2 (en) 2014-09-08 2017-01-17 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof

Families Citing this family (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379251B1 (en) 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
JP4394960B2 (en) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Akt activity inhibitor
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
EP1545515A1 (en) * 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
CA2527814A1 (en) * 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
JP2007516196A (en) * 2003-07-02 2007-06-21 ガラパゴス エヌブイ Pyrazine and pyralidine derivatives as Rho kinase inhibitors
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
KR20070064414A (en) * 2003-09-17 2007-06-20 이코스 코포레이션 Use of CHIH1 Inhibitors to Control Cell Proliferation
EP1680109A4 (en) 2003-10-07 2009-05-06 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
CA2545659C (en) * 2003-11-19 2013-06-04 Array Biopharma Inc. Bicyclic inhibitors of mek
KR101223914B1 (en) * 2003-11-21 2013-01-18 어레이 바이오파마 인크. Akt protein kinase inhibitors
US20070060588A1 (en) * 2003-12-22 2007-03-15 Jianguo Ji Fused bicycloheterocycle substituted quinuclidine derivatives
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137204A1 (en) * 2003-12-22 2005-06-23 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) * 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
JP2007526324A (en) * 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Inhibitors with AKT activity
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
KR100907108B1 (en) 2004-06-01 2009-07-09 에프. 호프만-라 로슈 아게 Pyridin-4-yl-ethynyl-imidazole and pyrazoles as MkL5 receptor antagonists
FR2871158A1 (en) * 2004-06-04 2005-12-09 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
AU2005256659A1 (en) * 2004-06-28 2006-01-05 Nycomed Gmbh 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
WO2006014359A2 (en) * 2004-07-02 2006-02-09 Icos Corporation Compounds useful for inhibiting chk1
AU2005269387A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101217958A (en) * 2004-08-23 2008-07-09 默克公司 Inhibitors of AKT activity
JP5275628B2 (en) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド Heterocyclic compounds and methods of use
WO2006034474A2 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
BRPI0606365A2 (en) * 2005-02-28 2017-06-27 Renovis Inc compound or a pharmaceutically acceptable salt, solvate or prodrug thereof and stereoisomers and tautomers thereof, pharmaceutical composition, methods for preventing, treating, ameliorating or controlling a disease or condition and for preparing a compound, use of a compound or a salt , solvate or pharmaceutically acceptable composition thereof, method of treating a mammal, and, combination
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2006094034A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver x receptor modilators
JP2008533166A (en) * 2005-03-16 2008-08-21 ターゲジェン インコーポレーティッド Pyrimidine compounds and methods of use
EA011287B1 (en) 2005-03-29 2009-02-27 Айкос Корпорейшн Heteroaryl urea derivatives useful for inhibiting chk1
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
PL2364973T3 (en) * 2005-05-18 2014-12-31 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
EP1893216A4 (en) * 2005-06-08 2012-08-08 Targegen Inc Methods and compositions for the treatment of ocular disorders
UA87929C2 (en) * 2005-06-10 2009-08-25 Мерк Энд Ко., Инк. INHIBITORS OF Akt ACTIVITY
PT1898903E (en) * 2005-06-10 2013-06-28 Merck Sharp & Dohme Inhibitors of akt activity
NZ592836A (en) 2005-07-27 2013-01-25 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
CA2620352A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
US7786120B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
CA2620269A1 (en) * 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
NL2000284C2 (en) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine derivatives.
EP1954699B1 (en) * 2005-11-22 2012-09-19 Kudos Pharmaceuticals Ltd PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2378473T3 (en) * 2005-12-21 2012-04-12 Abbott Laboratories Antiviral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
MX2008010635A (en) * 2006-02-16 2008-10-28 Schering Corp Pyrrolidine derivatives as erk inhibitors.
WO2007106884A2 (en) * 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
CN101454314A (en) * 2006-03-31 2009-06-10 先灵公司 Kinase inhibitors
HRP20110917T1 (en) 2006-05-19 2012-03-31 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
WO2007135398A1 (en) * 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101516891B (en) 2006-07-06 2013-06-05 阵列生物制药公司 Dihydrothieno pyrimidines as AKT protein kinase inhibitors
ES2372955T3 (en) 2006-07-06 2012-01-30 Array Biopharma, Inc. CICLOPENTA [D] PYRIMIDINS AS INHIBITORS OF THE PROTEIN CINASA AKT.
DE602007011628D1 (en) 2006-07-06 2011-02-10 Array Biopharma Inc DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
EP2057156B1 (en) 2006-08-23 2017-02-01 KuDOS Pharmaceuticals Limited 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008024977A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
US7776589B1 (en) 2006-08-31 2010-08-17 Schering Corporation Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)
GB0619325D0 (en) * 2006-09-30 2006-11-08 Univ Strathclyde New compounds
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
US7674091B2 (en) * 2006-11-14 2010-03-09 The Boeing Company Rotor blade pitch control
WO2008063558A2 (en) * 2006-11-17 2008-05-29 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
AR064010A1 (en) * 2006-12-06 2009-03-04 Merck & Co Inc AKT ACTIVITY INHIBITORS
EP2120951A4 (en) * 2006-12-06 2012-02-15 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
TWI399380B (en) 2006-12-20 2013-06-21 Abbott Lab Anti-viral compounds
WO2008082840A1 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
MX2009008253A (en) 2007-01-31 2009-10-12 Vertex Pharma Kinase inhibitors.
WO2008104869A1 (en) 2007-02-26 2008-09-04 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2692506C (en) * 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN101801955B (en) 2007-07-05 2013-05-08 阵列生物制药公司 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8314131B2 (en) * 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
KR20100093552A (en) 2007-11-02 2010-08-25 버텍스 파마슈티칼스 인코포레이티드 [1h-pyrazolo[3,4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
MX2010005650A (en) 2007-11-21 2010-06-02 Abbott Lab Biaryl substituted diazabicycloalkane derivatives.
MX2010007546A (en) * 2008-01-09 2010-09-30 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor.
EP2247578B1 (en) * 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2254415B1 (en) * 2008-02-19 2013-01-23 Janssen Pharmaceutica, N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
KR20100117123A (en) * 2008-02-21 2010-11-02 쉐링 코포레이션 Compounds that are erk inhibitors
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
EP2303875B1 (en) * 2008-06-20 2012-11-28 AstraZeneca AB Compositions with and process for methylmorpholin-subsituted pyrido[2,3-d]pyrimidines
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JP5631310B2 (en) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Tricyclic pyrazolopyridine kinase inhibitors
CA2731451A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
WO2010017350A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
KR101323448B1 (en) 2008-10-02 2013-11-27 아사히 가세이 파마 가부시키가이샤 8-substituted isoquinoline derivative and use thereof
ES2554375T3 (en) 2008-11-25 2015-12-18 University Of Rochester MLK Inhibitors and Methods of Use
MX2011006503A (en) 2008-12-19 2011-09-06 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase.
UY32582A (en) * 2009-04-28 2010-11-30 Amgen Inc 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE
AU2010245914A1 (en) 2009-05-06 2011-12-15 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
AU2010247391A1 (en) 2009-05-15 2011-12-01 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
EP2430011A1 (en) 2009-05-15 2012-03-21 Novartis AG 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
JP2013501792A (en) * 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Indazole and its therapeutic use as WNT / B-catenin signaling pathway inhibitor
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
JP2013518112A (en) * 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazolopyridine kinase inhibitor
CN102858769A (en) * 2010-01-27 2013-01-02 沃泰克斯药物股份有限公司 Pyrazolopyridine kinase inhibitors
CN102869664A (en) 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 Pyrazolopyrimidine kinase inhibitors
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143426A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
CN112915092A (en) 2011-04-01 2021-06-08 基因泰克公司 Combinations of AKT inhibitor compounds and abiraterone and methods of use
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
JP6212045B2 (en) 2011-09-30 2017-10-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Process for making compounds useful as inhibitors of ATR kinase
EP3733185B1 (en) 2011-09-30 2022-12-07 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
TW201329025A (en) 2011-11-01 2013-07-16 Astex Therapeutics Ltd Pharmaceutical compound
EP2776423B1 (en) 2011-11-11 2020-05-06 Georgetown University Phenyl-substituted nicotinic ligands, and methods of use thereof
SG10201912411RA (en) 2011-12-28 2020-02-27 Univ California Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (en) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
CN108478577A (en) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 It can be used as the compound of ATR kinase inhibitors and combinations thereof therapy
US20150225404A1 (en) 2012-08-30 2015-08-13 Nippon Shinyaku Co., Ltd. Pyridine derivative and medicine
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
JP6355648B2 (en) 2013-01-08 2018-07-11 サミュメッド リミテッド ライアビリティ カンパニー 3- (Benzimidazol-2-yl) -indazole inhibitors of WNT signaling pathway and their therapeutic use
AR094812A1 (en) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
DK2964229T3 (en) 2013-03-06 2020-01-27 Janssen Pharmaceutica Nv BENZOIMIDAZOLE-2-YL PYRIMIDINE MODULATORS OF THE HISTAMIN-H4 RECEPTOR
AU2014237348C1 (en) 2013-03-15 2019-02-07 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN112500338A (en) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20150132146A (en) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2968371T3 (en) 2013-10-10 2024-05-09 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
EP3068758B1 (en) 2013-11-15 2021-09-08 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
MY184366A (en) 2014-02-14 2021-04-01 Takeda Pharmaceuticals Co Pyrazines modulators of gpr6
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US9745271B2 (en) 2014-03-20 2017-08-29 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
JP6411541B2 (en) * 2014-04-02 2018-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Biaryl kinase inhibitor
CR20160493A (en) 2014-04-25 2016-12-16 Pfizer HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE DIGINATES D1
AR101198A1 (en) 2014-07-16 2016-11-30 Gruenenthal Gmbh PYRIMIDINES 2,5-REPLACED AS PDE4B INHIBITORS
AR101196A1 (en) 2014-07-16 2016-11-30 Gruenenthal Gmbh SUBSTITUTED PYRIMIDINE COMPOUNDS
CA2956270C (en) 2014-08-18 2022-08-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
JP6746569B2 (en) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104370813A (en) * 2014-10-22 2015-02-25 上海大学 Preparation method of isoquinoline-6-formaldehyde
CN104610229B (en) * 2015-01-21 2017-01-18 上海皓元生物医药科技有限公司 Synthesis method of ATP competitive small-molecule AKT inhibitor A443654
US20180015079A1 (en) 2015-03-25 2018-01-18 National Cancer Center Therapeutic agent for bile duct cancer
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
EP3294705B1 (en) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
CN106265660B (en) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 Application of A674563 in acute leukemia carrying FLT3 mutant gene
JP6936796B2 (en) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド Histone deacetylase heterohalo inhibitor
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CA2998397A1 (en) 2015-09-09 2017-03-16 Warren C. Lau Methods, compositions, and uses of novel fyn kinase inhibitors
MX395066B (en) 2015-09-30 2025-03-24 Vertex Pharma METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) INHIBITORS.
CN108430986B (en) 2015-10-26 2021-08-31 拜耳作物科学股份公司 Fused Bicyclic Heterocyclic Derivatives as Pest Control Agents
CN108473491A (en) 2015-11-06 2018-08-31 萨穆梅德有限公司 2- (1H- indazole -3- bases) -3H- imidazos [4,5-C] pyridines and its antiphlogistic use
MX384797B (en) 2015-12-04 2025-03-14 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG10201913213WA (en) 2015-12-17 2020-03-30 Eisai R&D Man Co Ltd Therapeutic agent for breast cancer
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
AR108435A1 (en) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE
SMT202200486T1 (en) 2016-06-01 2023-01-13 Biosplice Therapeutics Inc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
JP6946412B2 (en) 2016-07-18 2021-10-06 ヤンセン ファーマシューティカ エヌ．ベー． Tau PET Imaging Ligand
TWI778983B (en) 2016-10-12 2022-10-01 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2018075858A1 (en) 2016-10-21 2018-04-26 Samumed, Llc Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
MA46696A (en) 2016-11-07 2019-09-11 Samumed Llc READY-TO-USE SINGLE-DOSE INJECTABLE FORMULATIONS
EP3541431B1 (en) * 2016-11-16 2024-04-17 The General Hospital Corporation Myeloperoxidase imaging agents
LT3570834T (en) 2017-01-11 2022-03-10 Alkermes, Inc. BICYCLIC HISTON DEACETYLASE INHIBITORS
JP2020507625A (en) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
BR112019016248A2 (en) 2017-02-07 2020-04-14 Oblique Therapeutics Ab hydrocarbylsulfonyl substituted pyridines and their use in cancer treatment
WO2018146471A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
JP2020507624A (en) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー Sulfinylpyridines and their use in the treatment of cancer
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
LT3664802T (en) 2017-08-07 2022-06-27 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
CN111712245A (en) 2018-03-28 2020-09-25 卫材R&D管理有限公司 Therapeutic agents for hepatocellular carcinoma
TW201946919A (en) 2018-05-17 2019-12-16 威斯塔研究所 EBNA1 inhibitor crystalline forms, and methods of preparing and using same
MX2021003158A (en) 2018-09-18 2021-07-16 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors.
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2022058344A1 (en) 2020-09-18 2022-03-24 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
KR20230107551A (en) * 2020-09-28 2023-07-17 카듀리온 파마슈티칼스, 인크. Fused Heteroaryl Compounds and Their Use as CAMKII Inhibitors
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
EP4173674A1 (en) * 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
CN115353508B (en) * 2022-08-24 2023-07-21 中国药科大学 5-pyridine-1H-indazole compound, pharmaceutical composition and application
CN115417816B (en) * 2022-09-05 2024-01-26 江苏南大光电材料股份有限公司 Preparation method of 3, 6-dibromo-1-chloro-isoquinoline
EP4587439A1 (en) 2022-09-16 2025-07-23 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
AU2024210779A1 (en) * 2023-01-20 2025-07-31 Dermbiont, Inc. Compositions and formulations for the prevention, treatment, and improvement of skin diseases, conditions, and disorders
AR131690A1 (en) * 2023-01-30 2025-04-23 Eurofarma Laboratorios S A PHENOLIC COMPOUNDS BLOCKING Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, THEIR COMPOSITIONS, THEIR USES, THEIR TREATMENT METHODS AND KITS
WO2024159287A1 (en) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting hydroxamates, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
AR131715A1 (en) * 2023-01-30 2025-04-23 Eurofarma Laboratorios S A Nav 1.7 and/or Nav 1.8 blocking amides, their production processes, compositions, uses, treatment methods and kits

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179563A (en) * 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
WO1993010114A1 (en) * 1991-11-20 1993-05-27 Smithkline Beecham Plc 3-pyridinol derivatives and their use as medicaments
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1999031088A1 (en) * 1997-12-12 1999-06-24 Abbott Laboratories Triazine angiogenesis inhibitors
WO1999058523A1 (en) * 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
WO1999061406A2 (en) * 1998-05-22 1999-12-02 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6030969A (en) * 1998-04-09 2000-02-29 Abbott Laboratories 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
WO2000010997A1 (en) * 1998-08-25 2000-03-02 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2001019817A2 (en) * 1999-09-14 2001-03-22 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
WO2001019829A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Pyrazolopyrimidines as therapeutic agents
WO2001057018A1 (en) * 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2001070687A1 (en) * 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
WO2001081316A2 (en) * 2000-04-27 2001-11-01 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002050065A2 (en) * 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9611797D0 (en) 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
DE69716916T2 (en) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
ATE260898T1 (en) 1996-09-25 2004-03-15 Ss Pharmaceutical Co SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SAME
ATE554750T1 (en) 1997-03-05 2012-05-15 Sugen Inc PREPARATIONS CONTAINING HYDROPHOBIC PHARMACEUTICAL ACTIVE INGREDIENTS
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JP4528440B2 (en) 1998-05-29 2010-08-18 スージェン， インク． Pyrrole substituted 2-indolinone protein kinase inhibitor
AU4685799A (en) 1998-06-17 2000-01-05 Geron Corporation Telomerase inhibitors
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6525072B1 (en) 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
KR20010085841A (en) 1998-09-25 2001-09-07 클래스 하인츠-게르트 Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes
US6462036B1 (en) * 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
KR20010108063A (en) 1998-12-31 2001-12-07 수젠, 인크. 3-Heteroarylidenyl-2-Indolinone Compounds for Modulating Protein Kinase Activity and for Use in Cancer Chemotherapy
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
CA2368041A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
ATE316527T1 (en) 1999-08-27 2006-02-15 Boehringer Ingelheim Pharma SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS
DE19949209A1 (en) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma 5-substituted indolinones, their preparation and their use as pharmaceuticals
UA75054C2 (en) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
CA2386889A1 (en) 1999-10-26 2001-05-03 The University Of Texas Southwestern Medical Center Methods of treating hair loss comprising administering indoline compound
EP1259234B9 (en) 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
EP1294709A2 (en) 2000-01-28 2003-03-26 AstraZeneca AB Quinoline derivatives and their use as aurora 2 kinase inhibitors
SK287142B6 (en) 2000-02-15 2010-01-07 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmacutical composition and use
MXPA02007957A (en) 2000-02-17 2002-11-29 Amgen Inc Kinase inhibitors.
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001066708A2 (en) 2000-03-08 2001-09-13 Zealand Pharma A/S MATERIALS AND METHODS RELATING TO THE DEGRADATION OF Cdc25A IN RESPONSE TO DNA DAMAGE
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179563A (en) * 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
WO1993010114A1 (en) * 1991-11-20 1993-05-27 Smithkline Beecham Plc 3-pyridinol derivatives and their use as medicaments
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6127386A (en) * 1996-06-06 2000-10-03 Abbott Laboratories 3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1999031088A1 (en) * 1997-12-12 1999-06-24 Abbott Laboratories Triazine angiogenesis inhibitors
US6030969A (en) * 1998-04-09 2000-02-29 Abbott Laboratories 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
WO1999058523A1 (en) * 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
WO1999061406A2 (en) * 1998-05-22 1999-12-02 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
WO2000010997A1 (en) * 1998-08-25 2000-03-02 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2001019817A2 (en) * 1999-09-14 2001-03-22 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
WO2001019829A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Pyrazolopyrimidines as therapeutic agents
WO2001057018A1 (en) * 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2001070687A1 (en) * 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
WO2001081316A2 (en) * 2000-04-27 2001-11-01 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002050065A2 (en) * 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (1998), 8(19), 2797-2802 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000), 10(10), 1063-1066 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(5), 631-633 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HOLLADAY, MARK W. ET AL: "Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice", XP002240028, retrieved from STN Database accession no. 130:75736 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LEE, JUNG ET AL: "Synthesis and structure-activity relationship of novel pyridyl ethers for the nicotinic acetylcholine receptor", XP002240027, retrieved from STN Database accession no. 133:171774 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIN, N.-H. ET AL: "Synthesis and structure-activity relationships of 5-substituted pyridine analogues of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic receptor ligand", XP002240026, retrieved from STN Database accession no. 135:19528 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524957B2 (en) 2001-08-17 2009-04-28 Astrazeneca Ab Compounds effecting glucokinase
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7642263B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7655662B2 (en) 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US9381192B2 (en) 2009-08-10 2016-07-05 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US8895573B2 (en) 2009-10-30 2014-11-25 Janssen Pharmaceutica, Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
US8183371B2 (en) 2009-10-30 2012-05-22 Janssen Pharmaceutica Nv Pyrazines as delta opioid receptor modulators
US8293750B2 (en) 2009-10-30 2012-10-23 Janssen Pharmaceutica Nv Pyrazines as delta opioid receptor modulators
US8394809B2 (en) 2009-10-30 2013-03-12 Janssen Pharmaceutica, Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
US8513271B2 (en) 2009-10-30 2013-08-20 Janssen Pharmaceutica, Nv Pyrimidine compounds as delta opioid receptor modulators
US8685990B2 (en) 2009-10-30 2014-04-01 Janssen Pharmaceutica, Nv Pyrimidine compounds as delta opioid receptor modulators
US8901150B2 (en) 2009-12-21 2014-12-02 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8846714B2 (en) 2009-12-21 2014-09-30 Samumed, Llc 1H-pyrazolo[3,4-β]pyridines and therapeutic uses thereof
US9446035B2 (en) 2009-12-21 2016-09-20 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US9221793B2 (en) 2011-09-14 2015-12-29 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US8987298B2 (en) 2012-04-04 2015-03-24 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US9199991B2 (en) 2012-04-04 2015-12-01 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9586977B2 (en) 2012-05-04 2017-03-07 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US9012472B2 (en) 2012-05-04 2015-04-21 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US9233104B2 (en) 2012-05-04 2016-01-12 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8883822B2 (en) 2012-05-04 2014-11-11 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9475807B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof
US9475825B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9493487B2 (en) 2014-09-08 2016-11-15 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US9540398B2 (en) 2014-09-08 2017-01-10 Samumed, Llc 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9546185B2 (en) 2014-09-08 2017-01-17 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof

Also Published As

Publication number Publication date
US6831175B2 (en) 2004-12-14
US20030199511A1 (en) 2003-10-23
WO2003051366A2 (en) 2003-06-26
US20030187026A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
WO2003051366A3 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
WO2007079164A3 (en) Protein kinase inhibitors
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
PL1635835T3 (en) 2-aminopyrimidine derivatives as raf kinase inhibitors
MXPA03010961A (en) Thiazole compounds useful as inhibitors of protein kinases.
WO2006070195A8 (en) Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
MXPA02005844A (en) Inhibitors of protein kinases.
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2008017361A3 (en) 2-(heterocyclylbenzyl)pyridazinone derivatives
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2006004636A3 (en) Fused heterocyclic kinase inhibitors
WO2001060814A3 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
CA2400447A1 (en) Kinase inhibitors
MXPA05009151A (en) Heterocyclic kinase inhibitors.
WO2000043373A3 (en) Kinase inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2006047503A3 (en) Inhibitors of c-fms kinase
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
WO2007012972A3 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005810

Country of ref document: MX

Ref document number: 2003552299

Country of ref document: JP

Ref document number: 2470214

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002790126

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002790126

Country of ref document: EP